
  
    
      
        Synopsis_NNP
        
          Introduction_NNP
          A_DT reduction_NN in_IN the_DT sex_NN ratio_NN (_( male_JJ :_: female_JJ )_) is_VBZ
          characteristic_NN of_IN most_JJS autoimmune_JJ disorders_NNS ._. The_DT
          increased_VBN prevalence_NN in_IN females_NNS ranges_NNS from_IN a_DT modest_JJ 2_CD :_: 1_CD
          for_IN multiple_JJ sclerosis_NN [_NN 1_CD ]_NN ,_, to_TO approximately_RB 10_CD :_: 1_CD for_IN
          systemic_JJ lupus_JJ erythematosus_JJ [_NN 2_CD ]_NN ._. This_DT tendency_NN toward_IN
          autoimmunity_NN in_IN females_NNS is_VBZ often_RB ascribed_VBN to_TO hormonal_NN
          differences_NNS ,_, because_IN in_IN a_DT number_NN of_IN experimental_JJ disease_NN
          models_NNS estrogens_NNS exacerbated_VBD disease_NN ,_, and_CC androgens_NNS can_MD
          inhibit_VB disease_NN activity_NN [_NN 3_CD ,_, 4_CD ]_NN ._. However_RB ,_, human_JJ studies_NNS
          have_VBP failed_VBN to_TO demonstrate_VB a_DT clear-cut_JJ influence_NN of_IN
          hormonal_NN environment_NN on_IN disease_NN susceptibility_NN to_TO lupus_JJ
          or_CC other_JJ autoimmune_JJ disorders_NNS ._. In_IN addition_NN ,_, many_JJ
          childhood_NN forms_NNS of_IN autoimmunity_NN ,_, such_JJ as_IN juvenile_JJ
          rheumatoid_NN arthritis_NN ,_, exhibit_NN female_JJ predominance_NN [_NN 5_CD ]_NN ._.
          Interestingly_RB ,_, juvenile_JJ (_( type_NN 1_LS )_) diabetes_NN is_VBZ an_DT exception_NN
          to_TO this_DT general_JJ trend_NN ,_, with_IN a_DT sex_NN ratio_NN close_RB to_TO 1_CD in_IN
          most_JJS studies_NNS [_NN 6_CD ]_NN ._. Therefore_RB ,_, it_PRP is_VBZ reasonable_JJ to_TO
          consider_VB alternative_JJ explanations_NNS for_IN the_DT increased_VBN
          prevalence_NN of_IN autoimmune_JJ diseases_NNS in_IN human_JJ females_NNS ._.
          A_DT unifying_JJ feature_NN of_IN autoimmune_JJ disorders_NNS appears_VBZ to_TO
          be_VB the_DT loss_NN of_IN immunologic_JJ tolerance_NN to_TO self-antigens_JJ ,_,
          and_CC in_IN many_JJ of_IN these_DT diseases_NNS there_RB is_VBZ evidence_NN that_IN
          T-_NNP cell_NN tolerance_NN has_VBZ been_VBN broken_VBN ._. The_DT most_RBS profound_JJ form_NN
          of_IN T-_NNP cell_NN tolerance_NN involves_VBZ deletion_NN of_IN potentially_RB
          self-reactive_JJ T_NN cells_NNS during_IN thymic_JJ selection_NN ._. Thus_RB ,_, lack_NN
          of_IN exposure_NN to_TO a_DT self-antigen_JJ in_IN the_DT thymus_JJ may_MD lead_VB to_TO
          the_DT presence_NN of_IN autoreactive_JJ T_NN cells_NNS and_CC may_MD increase_VB the_DT
          risk_NN of_IN autoimmunity_NN ._. An_DT elegant_JJ example_NN of_IN this_DT has_VBZ
          recently_RB been_VBN reported_VBN [_NN 7_CD ]_NN ._.
          The_DT existence_NN of_IN X-_NNP chromosome_NN inactivation_NN in_IN females_NNS
          offers_VBZ a_DT potential_JJ mechanism_NN whereby_WRB X-_NNP linked_VBD
          self-antigens_JJ may_MD escape_VB presentation_NN in_IN the_DT thymus_JJ or_CC in_IN
          other_JJ peripheral_JJ sites_NNS that_WDT are_VBP involved_VBN in_IN tolerance_NN
          induction_NN ._. Early_RB in_IN female_JJ development_NN ,_, one_CD of_IN the_DT two_CD X_NNP
          chromosomes_NNS in_IN each_DT cell_NN undergoes_NNS an_DT ordered_VBN process_NN of_IN
          inactivation_NN ,_, with_IN subsequent_JJ silencing_VBG of_IN most_JJS genes_NNS on_IN
          the_DT inactive_JJ X_NNP chromosome_NN [_NN 8_CD ]_NN ._. This_DT phenomenon_NN occurs_VBZ at_IN
          a_DT very_RB early_JJ embryonic_JJ stage_NN [_NN 9_CD ]_NN ,_, and_CC thus_RB all_DT females_NNS
          are_VBP mosaic_JJ and_CC may_MD occasionally_RB exhibit_VB extreme_JJ skewing_VBG
          towards_IN one_CD or_CC the_DT other_JJ parental_JJ X_NNP chromosome_NN ._. In_IN
          theory_NN ,_, this_DT may_MD result_VB in_IN a_DT situation_NN in_IN which_WDT
          polymorphic_JJ self-antigens_JJ on_IN one_CD X_NNP chromosome_NN may_MD fail_VB to_TO
          be_VB expressed_VBN at_IN sufficiently_RB high_JJ levels_NNS in_IN a_DT tolerizing_VBG
          compartment_NN ,_, such_JJ as_IN the_DT thymus_JJ ,_, and_CC yet_RB may_MD be_VB expressed_VBN
          at_IN a_DT considerable_JJ frequency_NN in_IN the_DT peripheral_JJ soma_NN ._. Thus_RB ,_,
          females_NNS may_MD be_VB predisposed_JJ to_TO a_DT situation_NN in_IN which_WDT they_PRP
          can_MD occasionally_RB express_VB X-_NNP linked_VBD autoantigens_NNS in_IN the_DT
          periphery_NN to_TO which_WDT they_PRP have_VBP been_VBN inefficiently_RB
          tolerized_JJ ._. Stewart_NNP [_NN 10_CD ]_NN has_VBZ recently_RB speculated_VBN that_IN
          such_JJ a_DT mechanism_NN may_MD play_VB a_DT role_NN in_IN the_DT predisposition_NN to_TO
          systemic_JJ lupus_JJ ._.
          This_DT hypothesis_NNS predicts_VBZ that_IN females_NNS with_IN
          autoimmunity_NN may_MD be_VB particularly_RB prone_JJ to_TO this_DT mechanism_NN
          of_IN `_`` inadequate_JJ tolerization_NN '_'' by_IN virtue_NN of_IN extremely_RB
          skewed_VBN X-_NNP chromosome_NN inactivation_NN ._. We_PRP therefore_RB performed_VBD
          a_DT comprehensive_JJ analysis_NN of_IN X-_NNP chromosome_NN inactivation_NN
          patterns_NNS in_IN populations_NNS of_IN females_NNS with_IN multiple_JJ
          sclerosis_NN ,_, systemic_JJ lupus_JJ erythematosus_JJ ,_, juvenile_JJ
          rheumatoid_NN arthritis_NN ,_, and_CC type_NN 1_CD (_( insulin-dependent_JJ )_)
          diabetes_NN mellitus_JJ ,_, and_CC in_IN female_JJ control_NN individuals_NNS ._. The_DT
          results_NNS do_VBP not_RB provide_VB support_NN for_IN a_DT major_JJ role_NN for_IN
          skewed_VBN X-_NNP chromosome_NN inactivation_NN in_IN female_JJ predisposition_NN
          to_TO autoimmunity_NN ;_: however_RB ,_, neither_DT is_VBZ the_DT underlying_VBG
          hypothesis_NNS disproved_JJ by_IN the_DT present_JJ data_NN ._.
        
        
          Materials_NNS and_CC method_NN
          DNA_NNP was_VBD obtained_VBN from_IN female_JJ patients_NNS from_IN the_DT
          following_JJ sources_NNS :_: 45_CD persons_NNS with_IN juvenile_JJ diabetes_NN seen_VBN
          at_IN the_DT Virginia_NNP Mason_NNP Research_NNP Center_NNP in_IN Seattle_NNP ,_,
          Washington_NNP ;_: 58_CD multiple_JJ sclerosis_NN patients_NNS seen_VBN at_IN the_DT
          New_NNP York_NNP Hospital_NNP Multiple_NNP Sclerosis_NNP Center_NNP ;_: 46_CD patients_NNS
          with_IN systemic_JJ lupus_JJ erythematosus_JJ seen_VBN at_IN the_DT Hospital_NNP
          for_IN Special_JJ Surgery_NNP (_( New_NNP York_NNP )_) ;_: 18_CD patients_NNS with_IN juvenile_JJ
          rheumatoid_NN arthritis_NN seen_VBN at_IN the_DT Children_NNP 's_POS Hospital_NNP
          Medical_NNP Center_NNP in_IN Cleveland_NNP ._. In_IN addition_NN ,_, 30_CD healthy_JJ
          age-matched_JJ females_NNS were_VBD studied_VBN as_IN normal_JJ controls_NNS ._.
          Employing_NNP a_DT modification_NN of_IN previously_RB described_VBD
          methods_NNS [_NN 11_CD ]_NN ,_, we_PRP utilized_JJ a_DT fluorescent_NN Hpa_NNP II_NNP /_NN PCR_NNP assay_NN
          of_IN the_DT androgen_NN receptor_NN (_( AR_NNP )_) locus_JJ to_TO assess_VB
          X-_NNP chromosome_NN inactivation_NN patterns_NNS ._. The_DT AR_NNP gene_NN contains_VBZ
          a_DT polymorphic_JJ CAG_NNP repeat_NN ,_, which_WDT is_VBZ flanked_JJ by_IN Hpa_NNP II_NNP
          sites_NNS ._. These_DT Hpa_NNP II_NNP sites_NNS are_VBP methylated_JJ on_IN the_DT inactive_JJ
          X_NNP chromosome_NN ,_, and_CC are_VBP unmethylated_JJ on_IN the_DT active_JJ X_NNP
          chromosome_NN ._. By_IN performing_VBG PCR_NNP amplification_NN across_IN this_DT
          region_NN after_IN cutting_VBG with_IN the_DT methylation-sensitive_JJ
          enzyme_NN Hpa_NNP II_NNP ,_, the_DT relative_JJ amounts_NNS of_IN the_DT methylated_JJ AR_NNP
          alleles_NNS can_MD be_VB quantitatively_RB determined_VBN with_IN a_DT high_JJ
          degree_NN of_IN accuracy_NN ;_: variance_NN on_IN repeated_VBN assays_NNS is_VBZ
          approximately_RB 4_CD %_NN [_NN 12_CD ]_NN ._.
          Skewing_NNP of_IN X-_NNP chromosome_NN inactivation_NN is_VBZ expressed_VBN as_IN
          percentage_NN deviation_NN from_IN equal_JJ (_( 50_CD :_: 50_CD )_) inactivation_NN of_IN
          the_DT upper_JJ and_CC lower_JJR AR_NNP alleles_NNS ._. Therefore_RB ,_, the_DT maximal_NN
          possible_JJ deviation_NN is_VBZ 50_CD %_NN ,_, in_IN which_WDT case_NN all_DT of_IN the_DT X_NNP
          chromosomes_NNS bearing_NN one_CD of_IN the_DT AR_NNP alleles_NNS are_VBP
          inactivated_JJ ._.
        
        
          Results_NNS
          We_PRP examined_VBD X-_NNP chromosome_NN inactivation_NN patterns_NNS in_IN
          several_JJ different_JJ populations_NNS ._. The_DT results_NNS are_VBP summarized_VBD
          in_IN Fig_NNP ._. 1_LS ._. A_DT wide_JJ range_NN of_IN X-_NNP inactivation_NN skewing_VBG was_VBD
          observed_VBN in_IN all_DT five_CD groups_NNS ._. Approximately_RB 5_CD %_NN (_( nine_CD out_IN
          of_IN 197_CD )_) of_IN individuals_NNS exhibited_VBN extreme_JJ skewing_VBG (_( greater_JJR
          than_IN 40_CD %_NN deviation_NN from_IN a_DT 50_CD :_: 50_CD distribution_NN )_) ._. However_RB ,_,
          there_EX was_VBD no_DT difference_NN between_IN the_DT groups_NNS ,_, either_CC in_IN the_DT
          overall_JJ mean_NN skewing_VBG ,_, or_CC in_IN the_DT fraction_NN of_IN individuals_NNS
          with_IN extreme_JJ skewing_VBG (_( >_NN 40_CD %_NN )_) ._.
          Although_IN the_DT present_JJ study_NN was_VBD not_RB initiated_VBN in_IN order_NN
          to_TO examine_VB allelic_JJ variation_NN in_IN the_DT AR_NNP gene_NN 
          per_IN se_FW ,_, the_DT data_NNS provide_VBP an_DT
          opportunity_NN to_TO address_VB this_DT question_NN ._. Excessively_NNP long_JJ
          CAG_NNP repeats_VBZ in_IN the_DT AR_NNP are_VBP a_DT rare_JJ cause_NN of_IN spinal-bulbar_JJ
          muscular_JJ atrophy_NN [_NN 13_CD ]_NN ,_, and_CC AR_NNP repeat_NN length_NN appears_VBZ to_TO
          have_VB an_DT influence_NN on_IN the_DT biology_NN of_IN certain_JJ tumors_NNS [_NN 14_CD ,_,
          15_CD ]_NN ._. In_IN this_DT context_NN ,_, it_PRP has_VBZ been_VBN shown_VBN that_DT
          transcription_NN of_IN AR_NNP correlates_NNS inversely_RB with_IN repeat_NN
          length_NN [_NN 16_CD ]_NN ._. We_PRP therefore_RB compared_VBD AR_NNP repeat_NN length_NN in_IN
          control_NN individuals_NNS and_CC patients_NNS with_IN autoimmunity_NN ._. No_DT
          differences_NNS were_VBD observed_VBN for_IN mean_NN repeat_NN length_NN ,_, or_CC for_IN
          maximum_NN and_CC minimum_JJ repeat_NN length_NN ,_, among_IN the_DT five_CD
          groups_NNS ._.
        
        
          Discussion_NNP
          The_DT reason_NN for_IN the_DT female_JJ predominance_NN in_IN most_JJS
          autoimmune_JJ diseases_NNS remains_VBZ obscure_JJ ._. The_DT present_JJ study_NN
          was_VBD initiated_VBN in_IN order_NN to_TO address_VB the_DT hypothesis_NNS that_IN a_DT
          nonhormonal_NN mechanism_NN related_VBN to_TO X_NNP inactivation_NN might_MD be_VB
          involved_VBN ._. The_DT hypothesis_NNS rests_VBZ on_IN the_DT idea_NN that_IN skewing_VBG
          of_IN X_NNP inactivation_NN might_MD lead_VB to_TO a_DT deficiency_NN of_IN tolerance_NN
          induction_NN in_IN the_DT thymus_JJ ,_, particularly_RB with_IN respect_NN to_TO
          polymorphic_JJ X-_NNP linked_VBD autoantigens_NNS ._. The_DT hypothesis_NNS
          predicts_VBZ that_WDT skewed_VBN X_NNP inactivation_NN would_MD be_VB more_RBR
          prevalent_JJ in_IN females_NNS with_IN autoimmune_JJ diseases_NNS than_IN in_IN
          female_JJ control_NN individuals_NNS ._. This_DT was_VBD not_RB observed_VBN ._.
          Nevertheless_RB ,_, these_DT negative_JJ data_NN do_VBP not_RB rule_VB out_RP a_DT
          role_NN for_IN X_NNP inactivation_NN in_IN female_JJ predisposition_NN to_TO loss_NN
          of_IN tolerance_NN ._. A_DT general_JJ model_NN for_IN how_WRB this_DT mechanism_NN
          might_MD operate_VB is_VBZ shown_VBN in_IN Fig_NNP ._. 2_LS ._. Thymocytes_NNP undergo_VBP
          selection_NN in_IN the_DT thymic_JJ parenchyma_NN and_CC ,_, in_IN the_DT case_NN of_IN
          negative_JJ selection_NN ,_, the_DT selecting_VBG elements_NNS appear_VBP to_TO be_VB
          derived_VBN from_IN the_DT bone_NN marrow_NN and_CC consist_VBP mainly_RB of_IN thymic_JJ
          dendritic_JJ cells_NNS ._. If_IN the_DT thymic_JJ dendritic_JJ cell_NN population_NN
          exhibits_VBZ random_JJ X_NNP inactivation_NN ,_, it_PRP is_VBZ highly_RB likely_JJ that_IN
          differentiating_VBG thymocytes_NNS will_MD contact_VB dendritic_JJ cells_NNS
          that_WDT express_VBP self-antigens_JJ on_IN both_DT X_NNP chromosomes_NNS ._. This_DT
          situation_NN is_VBZ outlined_VBN schematically_RB on_IN the_DT left_NN side_NN of_IN
          Fig_NNP ._. 2_LS ._. However_RB ,_, if_IN there_EX is_VBZ extremely_RB skewed_VBN X_NNP
          inactivation_NN in_IN the_DT thymic_JJ dendritic_JJ cell_NN population_NN ,_, a_DT
          particular_JJ thymocyte_NN might_MD not_RB come_VB into_IN contact_NN with_IN
          dendritic_JJ cells_NNS that_WDT express_VBP one_CD of_IN the_DT two_CD X_NNP
          chormosomes_NNS ._. This_DT would_MD lead_VB to_TO a_DT situation_NN where_WRB T_NN cells_NNS
          may_MD undergo_VB thymic_JJ maturation_NN without_IN having_VBG been_VBN
          negatively_RB selected_VBN for_IN antigens_NNS that_WDT are_VBP expressed_VBN on_IN
          the_DT predominantly_RB inactive_JJ X_NNP chromosome_NN ._. This_DT situation_NN
          is_VBZ shown_VBN on_IN the_DT right_JJ side_NN of_IN Fig_NNP ._. 2_LS ._.
          In_IN order_NN for_IN this_DT mechanism_NN to_TO be_VB physiologically_RB
          relevant_JJ ,_, some_DT assumptions_NNS must_MD be_VB made_VBN ._. First_LS ,_, defective_JJ
          tolerance_NN from_IN skewed_VBN X_NNP inactivation_NN should_MD only_RB be_VB
          directed_VBN at_IN X-_NNP linked_VBD antigens_NNS that_WDT are_VBP polymorphic_JJ ,_, and_CC
          for_IN which_WDT the_DT individual_NN is_VBZ heterozygous_JJ ._. Thus_RB ,_, this_DT
          mechanism_NN would_MD not_RB be_VB expected_VBN to_TO lead_VB to_TO lack_NN of_IN
          tolerance_NN commonly_RB ,_, unless_IN there_RB are_VBP at_IN least_JJS several_JJ
          highly_RB polymorphic_JJ X-_NNP linked_VBD autoantigens_NNS in_IN the_DT
          population_NN that_WDT are_VBP involved_VBN in_IN thymic_JJ deletion_NN events_NNS ._.
          Second_JJ ,_, if_IN this_DT actually_RB leads_VBZ to_TO autoimmunity_NN ,_, it_PRP also_RB
          predicts_VBZ that_IN the_DT initial_JJ break_NN in_IN tolerance_NN that_WDT leads_VBZ
          to_TO disease_NN should_MD involve_VB an_DT X-_NNP linked_VBD autoantigen_NN that_WDT is_VBZ
          expressed_VBN in_IN a_DT peripheral_JJ nontolerizing_VBG site_NN or_CC
          circumstance_NN ._.
          A_DT recent_JJ report_NN [_NN 7_CD ]_NN has_VBZ elegantly_RB demonstrated_VBN the_DT
          importance_NN of_IN thymic_JJ deletion_NN events_NNS in_IN predisposition_NN to_TO
          autoimmune_JJ disease_NN ._. The_DT proteolipid_NN protein_NN (_( PLP_NNP )_)
          autoantigen_NN is_VBZ expressed_VBN in_IN alternatively_RB spliced_JJ forms_NNS ,_,
          which_WDT exhibit_NN tissue_NN specific_JJ expression_NN ._. A_DT nonspliced_JJ
          variant_NN is_VBZ expressed_VBN in_IN peripheral_JJ neural_NN tissue_NN ._.
          However_RB ,_, in_IN the_DT thymus_JJ a_DT splice_NN variant_NN results_NNS in_IN the_DT
          lack_NN of_IN thymic_JJ expression_NN of_IN an_DT immunodominant_NN peptide_NN ._.
          This_DT results_NNS in_IN loss_NN of_IN tolerace_NN of_IN T_NN cells_NNS to_TO this_DT
          peptide_NN ,_, presumably_RB on_IN the_DT basis_NN of_IN lack_NN of_IN thymic_JJ
          deletion_NN of_IN thymocytes_NNS that_WDT are_VBP reactive_JJ with_IN this_DT
          antigen_NN ._. Interestingly_RB ,_, PLP_NNP is_VBZ encoded_JJ on_IN the_DT X_NNP
          chromsome_NN ._. However_RB ,_, there_EX is_VBZ no_DT evidence_NN that_IN genetic_JJ
          polymorphisms_NNS control_VBP the_DT level_NN splicing_VBG of_IN PLP_NNP within_IN
          the_DT thymus_JJ ._. Nevertheless_RB ,_, these_DT data_NNS illustrate_VBP the_DT
          potential_JJ importance_NN of_IN deficiencies_NNS in_IN thymic_JJ deletion_NN
          for_IN autoimmune_JJ T-_NNP cell_NN reactivity_NN ._.
          The_DT present_JJ results_NNS suggest_VBP that_IN if_IN skewed_VBN X_NNP
          inactivation_NN is_VBZ relevant_JJ to_TO thymic_JJ tolerance_NN induction_NN ,_,
          then_RB the_DT effect_NN does_VBZ not_RB depend_VB on_IN global_JJ skewing_VBG of_IN
          X-_NNP chromosome_NN inactivation_NN ,_, at_IN least_JJS in_IN the_DT hematopoietic_JJ
          compartment_NN ._. In_IN this_DT study_NN we_PRP examined_VBD X-_NNP inactivation_NN
          patterns_NNS in_IN peripheral_JJ blood_NN mononuclear_NN cells_NNS ,_, and_CC the_DT
          results_NNS should_MD reflect_VB the_DT state_NN of_IN X_NNP inactivation_NN in_IN all_DT
          mesenchymal_NN tissues_NNS ,_, including_VBG dendritic_JJ cells_NNS ._. X_NN
          inactivation_NN occurs_VBZ at_IN a_DT very_RB early_JJ time_NN point_NN in_IN
          development_NN ,_, and_CC thus_RB the_DT results_NNS in_IN one_CD tissue_NN should_MD
          reflect_VB the_DT general_JJ situation_NN in_IN the_DT rest_NN of_IN the_DT body_NN ._.
          However_RB ,_, there_EX may_MD be_VB exceptions_NNS to_TO this_DT ._. We_PRP have_VBP
          occasionally_RB observed_VBN differences_NNS in_IN X-_NNP inactivation_NN
          patterns_NNS between_IN buccal_NN mucosa_NN (_( an_DT ectodermally_RB derived_VBN
          tissue_NN )_) and_CC peripheral_JJ blood_NN in_IN the_DT same_JJ individiual_NN
          (_( unpublished_JJ observations_NNS )_) ._. This_DT could_MD be_VB a_DT chance_NN event_NN ,_,
          or_CC it_PRP may_MD result_VB from_IN selection_NN for_IN certain_JJ X-_NNP linked_VBD
          alleles_NNS during_IN embryonic_JJ development_NN ,_, as_IN has_VBZ been_VBN
          described_VBN in_IN carriers_NNS of_IN X-_NNP linked_VBD immunodeficiencies_NNS [_NN
          17_CD ]_NN ._.
          Another_DT consideration_NN is_VBZ that_IN certain_JJ tissue_NN
          microenvironments_NNS may_MD be_VB derived_VBN from_IN very_RB small_JJ numbers_NNS
          of_IN founder_NN cells_NNS ,_, and_CC thus_RB may_MD exhibit_VB skewed_VBN utilization_NN
          of_IN one_CD or_CC the_DT other_JJ X_NNP chromosome_NN ,_, even_RB if_IN the_DT tissue_NN as_IN a_DT
          whole_NN is_VBZ not_RB skewed_VBN ._. This_DT situation_NN could_MD vary_VB over_IN time_NN ._.
          Thus_RB ,_, there_EX may_MD be_VB time_NN points_NNS at_IN which_WDT certain_JJ thymic_JJ
          microenvironments_NNS are_VBP populated_VBN by_IN dendritic_JJ cells_NNS that_IN ,_,
          for_IN stochastic_JJ reasons_NNS ,_, all_DT utilize_VB the_DT same_JJ X_NNP
          chromosome_NN ._. This_DT would_MD create_VB a_DT `_`` window_NN of_IN opportunity_NN '_''
          in_IN which_WDT a_DT given_VBN thymocyte_NN ,_, in_IN a_DT given_VBN selecting_VBG
          location_NN ,_, could_MD escape_VB negative_JJ selection_NN by_IN antigens_NNS on_IN
          the_DT inactive_JJ X_NNP chromosome_NN ._. The_DT likelihood_NN of_IN this_DT
          happening_VBG would_MD obviously_RB depend_VB on_IN the_DT number_NN of_IN
          dendritic_JJ cells_NNS that_WDT are_VBP usually_RB contacted_VBN by_IN a_DT thymocyte_NN
          during_IN thymic_JJ selection_NN ._. There_EX is_VBZ limited_VBN information_NN on_IN
          this_DT point_NN ,_, although_IN Stewart_NNP [_NN 10_CD ]_NN has_VBZ theorized_VBD that_IN
          this_DT number_NN may_MD be_VB as_RB low_JJ as_IN 15_CD ._. If_IN this_DT is_VBZ the_DT case_NN ,_,
          then_RB escape_VB from_IN thymic_JJ deletion_NN may_MD still_RB occur_VB in_IN
          females_NNS who_WP are_VBP heterozygous_JJ for_IN a_DT relevant_JJ X-_NNP linked_VBD
          antigen_NN ,_, even_RB if_IN the_DT hematopoietic_JJ cells_NNS in_IN general_JJ do_VBP
          not_RB exhibit_VB extreme_JJ skewing_VBG ._.
          In_IN conclusion_NN ,_, we_PRP suggest_VBP that_IN X-_NNP chromosome_NN
          inactivation_NN needs_VBZ to_TO be_VB considered_VBN as_IN a_DT potential_JJ factor_NN
          in_IN the_DT predominance_NN of_IN females_NNS in_IN most_JJS autoimmune_JJ
          diseases_NNS ._. Our_PRP$ inability_NN to_TO show_VB an_DT increase_NN in_IN
          X-_NNP chromosome_NN skewing_VBG in_IN females_NNS with_IN autoimmunity_NN does_VBZ
          not_RB eliminate_VB this_DT as_IN an_DT etiologic_JJ contributor_NN to_TO loss_NN of_IN
          immunologic_JJ tolerance_NN ._. Future_JJ experiments_NNS must_MD be_VB
          directed_VBN at_IN a_DT detailed_VBN analysis_NN of_IN tissue_NN patterns_NNS of_IN X_NNP
          inactivation_NN ,_, as_RB well_RB as_IN at_IN a_DT search_NN for_IN potential_JJ
          X-_NNP linked_VBD autoantigens_NNS ._.
        
      
      
        Introduction_NNP
        A_DT reduction_NN in_IN the_DT sex_NN ratio_NN (_( male_JJ :_: female_JJ )_) is_VBZ
        characteristic_NN of_IN most_JJS autoimmune_JJ disorders_NNS ._. The_DT increased_VBN
        prevalence_NN in_IN females_NNS ranges_NNS from_IN a_DT modest_JJ 2_CD :_: 1_CD for_IN multiple_JJ
        sclerosis_NN [_NN 1_CD ]_NN ,_, to_TO approximately_RB 10_CD :_: 1_CD for_IN systemic_JJ lupus_JJ
        erythematosus_JJ [_NN 2_CD ]_NN ._. This_DT tendency_NN towards_IN autoimmunity_NN in_IN
        females_NNS is_VBZ often_RB ascribed_VBN to_TO hormonal_NN differences_NNS because_IN ,_,
        in_IN a_DT number_NN of_IN experimental_JJ disease_NN models_NNS ,_, estrogens_NNS
        exacerbate_VB disease_NN and_CC androgens_NNS can_MD inhibit_VB disease_NN
        activity_NN [_NN 3_CD ,_, 4_CD ]_NN ._. However_RB ,_, human_JJ studies_NNS have_VBP failed_VBN to_TO
        demonstrate_VB a_DT clear-cut_JJ influence_NN of_IN hormonal_NN environment_NN
        on_IN disease_NN susceptibility_NN to_TO lupus_JJ or_CC other_JJ autoimmune_JJ
        disorders_NNS ._. In_IN addition_NN ,_, many_JJ childhood_NN forms_NNS of_IN
        autoimmunity_NN ,_, such_JJ as_IN juvenile_JJ rheumatoid_NN arthritis_NN ,_,
        exhibit_NN female_JJ predominance_NN [_NN 5_CD ]_NN ._. Interestingly_RB ,_, juvenile_JJ
        (_( type_NN 1_LS )_) diabetes_NN is_VBZ an_DT exception_NN to_TO this_DT general_JJ trend_NN ,_,
        with_IN a_DT sex_NN ratio_NN close_RB to_TO 1_CD in_IN most_JJS studies_NNS [_NN 6_CD ]_NN ._.
        Therefore_RB ,_, it_PRP is_VBZ reasonable_JJ to_TO consider_VB alternative_JJ
        explanations_NNS for_IN the_DT increased_VBN prevalence_NN of_IN autoimmune_JJ
        diseases_NNS in_IN human_JJ females_NNS ._.
        A_DT unifying_JJ feature_NN of_IN autoimmune_JJ disorders_NNS appears_VBZ to_TO be_VB
        the_DT loss_NN of_IN immunologic_JJ tolerance_NN to_TO self-antigens_JJ ,_, and_CC in_IN
        many_JJ of_IN these_DT diseases_NNS there_RB is_VBZ evidence_NN that_IN T-_NNP cell_NN
        tolerance_NN has_VBZ been_VBN broken_VBN ._. The_DT most_RBS profound_JJ form_NN of_IN T-_NNP cell_NN
        tolerance_NN involves_VBZ deletion_NN of_IN potentially_RB self-reactive_JJ T_NN
        cells_NNS during_IN thymic_JJ selection_NN ._. Thus_RB ,_, lack_NN of_IN exposure_NN to_TO a_DT
        self-antigen_JJ in_IN the_DT thymus_JJ may_MD lead_VB to_TO the_DT presence_NN of_IN
        autoreactive_JJ T_NN cells_NNS and_CC increase_VB the_DT risk_NN of_IN autoimmunity_NN ._.
        An_DT elegant_JJ example_NN of_IN this_DT has_VBZ recently_RB been_VBN reported_VBN [_NN
        7_CD ]_NN ._.
        The_DT existence_NN of_IN X-_NNP chromosome_NN inactivation_NN in_IN females_NNS
        offers_VBZ a_DT potential_JJ mechanism_NN whereby_WRB X-_NNP linked_VBD self-antigens_JJ
        may_MD escape_VB presentation_NN in_IN the_DT thymus_JJ or_CC in_IN other_JJ
        peripheral_JJ sites_NNS that_WDT are_VBP involved_VBN in_IN tolerance_NN induction_NN ._.
        Early_RB in_IN female_JJ development_NN ,_, one_CD of_IN the_DT two_CD X_NNP chromosomes_NNS
        in_IN each_DT cell_NN undergoes_NNS an_DT ordered_VBN process_NN of_IN inactivation_NN ,_,
        with_IN subsequent_JJ silencing_VBG of_IN most_JJS genes_NNS on_IN the_DT inactive_JJ X_NNP
        chromosome_NN [_NN 8_CD ]_NN ._. This_DT phenomenon_NN occurs_VBZ at_IN a_DT very_RB early_JJ
        embryonic_JJ stage_NN [_NN 9_CD ]_NN ,_, and_CC thus_RB all_DT females_NNS are_VBP mosaic_JJ and_CC
        may_MD occasionally_RB exhibit_VB extreme_JJ skewing_VBG towards_IN one_CD or_CC the_DT
        other_JJ parental_JJ X_NNP chromosome_NN ._. In_IN theory_NN ,_, this_DT may_MD result_VB in_IN
        a_DT situation_NN in_IN which_WDT polymorphic_JJ self-antigens_JJ on_IN one_CD X_NNP
        chromosome_NN may_MD fail_VB to_TO be_VB expressed_VBN at_IN sufficiently_RB high_JJ
        levels_NNS in_IN a_DT tolerizing_VBG compartment_NN ,_, such_JJ as_IN the_DT thymus_JJ ,_, and_CC
        yet_RB may_MD be_VB expressed_VBN at_IN considerable_JJ frequency_NN in_IN the_DT
        peripheral_JJ soma_NN ._. Thus_RB ,_, females_NNS may_MD be_VB predisposed_JJ to_TO a_DT
        situation_NN in_IN which_WDT they_PRP can_MD occasionally_RB express_VB X-_NNP linked_VBD
        autoantigens_NNS in_IN the_DT periphery_NN to_TO which_WDT they_PRP have_VBP been_VBN
        inefficiently_RB tolerized_JJ ._. Stewart_NNP [_NN 10_CD ]_NN has_VBZ recently_RB
        speculated_VBN that_IN such_JJ a_DT mechanism_NN may_MD play_VB a_DT role_NN in_IN the_DT
        predisposition_NN to_TO systemic_JJ lupus_JJ ._.
        This_DT hypothesis_NNS predicts_VBZ that_IN females_NNS with_IN autoimmunity_NN
        may_MD be_VB particularly_RB prone_JJ to_TO this_DT mechanism_NN of_IN `_`` inadequate_JJ
        tolerization_NN '_'' by_IN virtue_NN of_IN extremely_RB skewed_VBN X-_NNP chromosome_NN
        inactivation_NN ._. We_PRP therefore_RB performed_VBD a_DT comprehensive_JJ
        analysis_NN of_IN X-_NNP chromosome_NN inactivation_NN patterns_NNS in_IN
        populations_NNS of_IN females_NNS with_IN multiple_JJ sclerosis_NN ,_, systemic_JJ
        lupus_JJ ,_, juvenile_JJ rheumatoid_NN arthritis_NN ,_, and_CC type_NN 1_CD
        (_( insulin-dependent_JJ )_) diabetes_NN mellitus_JJ ,_, and_CC in_IN female_JJ
        control_NN individuals_NNS ._. The_DT results_NNS do_VBP not_RB provide_VB support_NN for_IN
        a_DT major_JJ role_NN for_IN skewed_VBN X-_NNP chromosome_NN inactivation_NN in_IN female_JJ
        predisposition_NN to_TO autoimmunity_NN ;_: however_RB ,_, neither_DT is_VBZ the_DT
        underlying_VBG hypothesis_NNS disproved_JJ by_IN our_PRP$ data_NNS ._.
      
      
        Materials_NNS and_CC method_NN
        
          Subjects_NNP
          DNA_NNP was_VBD obtained_VBN from_IN female_JJ patients_NNS from_IN the_DT
          following_JJ sources_NNS :_: 45_CD persons_NNS with_IN juvenile_JJ diabetes_NN seen_VBN
          at_IN the_DT Virginia_NNP Mason_NNP Research_NNP Center_NNP in_IN Seattle_NNP ,_,
          Washington_NNP ;_: 58_CD multiple_JJ sclerosis_NN patients_NNS seen_VBN at_IN the_DT
          New_NNP York_NNP Hospital_NNP Multiple_NNP Sclerosis_NNP Center_NNP ;_: 46_CD patients_NNS
          with_IN systemic_JJ lupus_JJ erythematosus_JJ seen_VBN at_IN the_DT Hospital_NNP
          for_IN Special_JJ Surgery_NNP (_( New_NNP York_NNP )_) ;_: 18_CD patients_NNS with_IN juvenile_JJ
          rheumatoid_NN arthritis_NN seen_VBN at_IN the_DT Children_NNP 's_POS Hospital_NNP
          Medical_NNP Center_NNP in_IN Cleveland_NNP ._. In_IN addition_NN ,_, 30_CD healthy_JJ
          age-matched_JJ females_NNS were_VBD studied_VBN as_IN normal_JJ controls_NNS ._.
        
        
          Hpa_NNP II_NNP /_NN polymerase_NN chain_NN reaction_NN assay_NN for_IN
          X-_NNP chromosome_NN inactivation_NN
          A_DT modification_NN to_TO a_DT previously_RB described_VBN assay_NN for_IN AR_NNP
          methylation_NN [_NN 11_CD ]_NN was_VBD used_VBN for_IN these_DT studies_NNS ._. In_IN the_DT
          normal_JJ females_NNS the_DT AR_NNP gene_NN is_VBZ methylated_JJ on_IN the_DT inactive_JJ
          X_NNP chromosome_NN and_CC is_VBZ undermethylated_JJ on_IN the_DT active_JJ X_NNP
          chromosome_NN ._. Furthermore_RB ,_, the_DT presence_NN of_IN a_DT highly_RB
          polymorphic_JJ triplet_NN repeat_NN within_IN the_DT AR_NNP gene_NN allows_VBZ for_IN
          the_DT discrimination_NN of_IN each_DT X_NNP chromosome_NN in_IN most_JJS female_JJ
          subjects_NNS (_( Fig_NNP ._. 3_LS )_) ._. Thus_RB ,_, allele-specific_JJ methylation_NN
          patterns_NNS can_MD be_VB distinguished_VBN using_VBG this_DT gene_NN ._.
          Genomic_NNP DNA_NNP (_( approximately_RB 200_CD ng_NN )_) was_VBD digested_VBN
          overnight_JJ using_VBG a_DT methylation-sensitive_JJ restriction_NN
          enzyme_NN HpaII_NNP ,_, as_IN per_IN the_DT manufacturer_NN 's_POS instructions_NNS
          (_( Gibco_NNP BRL_NNP ,_, Rockville_NNP ,_, MD_NNP ,_, USA_NNP )_) ._. A_DT mock_JJ sample_NN as_IN control_NN
          was_VBD prepared_VBN simultaneously_RB without_IN the_DT HpaII_NNP enzyme_NN ._.
          After_IN the_DT digestion_NN the_DT samples_NNS were_VBD boiled_VBD for_IN 10_CD min_NN to_TO
          inactivate_NN the_DT enzyme_NN ._. PCR_NNP amplification_NN was_VBD performed_VBN ,_,
          with_IN final_JJ concentration_NN of_IN the_DT digest_VB equivalent_JJ to_TO
          approximately_RB 100_CD ng_NN of_IN the_DT DNA_NNP ,_, 1_CD ×_NN PCR_NNP bufferII_NN
          (_( Perkin-_NNP Elmer_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, 2_CD ._. 5_CD mmol_NN /_NN l_NN MgCl_NNP 
          2_CD ,_, and_CC amplitaq_NN gold_NN 1_CD ._. 25_CD units_NNS ._.
          Primers_NNP used_VBD were_VBD AR_NNP 1_CD
          (_( 5_CD '_POS -_: TCCAGAATCTGTTCCA-GAGCGTGC-_NNP 3_CD '_POS )_) and_CC AR_NNP 2_CD
          (_( 5_CD '_POS -_: GCTGTGAAGGTTGCT-GTTCCTCAT-_NNP 3_CD '_POS )_) ._. These_DT primers_NNS flank_NN
          the_DT triple_JJ repeat_NN CAG_NNP and_CC the_DT HpaII_NNP sites_NNS in_IN the_DT first_JJ
          exon_NN of_IN the_DT AR_NNP gene_NN (_( Fig_NNP ._. 3_LS )_) ._. The_DT AR_NNP 1_CD primer_NN was_VBD
          fluorescence_NN labeled_VBN with_IN 6_CD -_: Fam_NNP and_CC TET_NNP ._. The_DT 6_CD -_: Fam-_NNP AR_NNP 1_CD
          and_CC the_DT TET-AR_NNP 1_CD were_VBD used_VBN for_IN mock_JJ and_CC HpaII-digested_NNP
          samples_NNS ,_, respectively_RB ._. This_DT combination_NN allowed_VBD
          simultaneous_JJ analyses_NNS of_IN the_DT PCR_NNP products_NNS of_IN the_DT HpaII-_NNP
          and_CC mock-treated_JJ samples_NNS using_VBG the_DT ABI_NNP 310_CD Genetic_NNP
          Analyzer_NNP (_( Perkin-_NNP Elmer_NNP )_) ._. The_DT final_JJ concentration_NN of_IN the_DT
          AR_NNP 1_CD primer_NN was_VBD 3_CD pmol_NN 6_CD -_: Fam-_NNP AR_NNP 1_CD +_NN 7_CD pmol_NN unlabelled_JJ AR_NNP 1_CD and_CC
          10_CD pmol_NN of_IN unlabeled_JJ AR_NNP 2_CD in_IN a_DT 50_CD μl_NN reaction_NN ._.
          The_DT cycling_NN conditions_NNS were_VBD as_IN follows_VBZ :_: denaturation_NN
          at_IN 95_CD °_NN C_NNP /_NN 12_CD min_NN to_TO activate_VBP the_DT amplitaq_NN gold_NN ,_, followed_VBN by_IN
          35_CD cycles_NNS of_IN denaturation_NN at_IN 95_CD °_NN C_NNP /_NN 45_CD s_VBZ ,_, annealing_VBG at_IN
          60_CD °_NN C_NNP /_NN 30_CD s_VBZ and_CC extension_NN at_IN 72_CD °_NN C_NNP /_NN 30_CD s_VBZ ._. After_IN 35_CD cycles_NNS ,_,
          the_DT final_JJ extension_NN was_VBD done_VBN at_IN 72_CD °_NN C_NNP /_NN 10_CD min_NN ._. The_DT PCR_NNP
          products_NNS of_IN each_DT sample_NN (_( mock_JJ and_CC HpaII_NNP )_) were_VBD diluted_VBN
          1_CD :_: 10_CD in_IN the_DT same_JJ vial_NN ._. One_CD microliter_NN of_IN the_DT diluted_VBN
          product_NN was_VBD then_RB added_VBN to_TO a_DT mixture_NN containing_VBG 12_CD μl_NN
          deionized_JJ formamide_NN and_CC 0_CD ._. 5_CD μl_NN molecular_JJ weight_NN standard_JJ
          GS_NNP 350_CD TAMRA_NNP ._. The_DT vials_NNS were_VBD denatured_JJ at_IN 95_CD °_NN C_NNP /_NN 5_CD min_NN ,_,
          cooled_VBN on_IN ice_NN ,_, and_CC resolved_VBD using_VBG a_DT 310_CD Genetic_NNP Analyzer_NNP
          (_( Perkin-_NNP Elmer_NNP )_) ._.
        
        
          Calculations_NNP for_IN percentage_NN of_IN skewing_VBG of_IN X_NNP
          inactivation_NN
          Two_CD peaks_NNS corresponding_JJ to_TO two_CD alleles_NNS were_VBD obtained_VBN
          from_IN the_DT 310_CD Genetic_NNP Analyzer_NNP for_IN each_DT mock-_NN and_CC
          HpaII-treated_NNP sample_NN ._. The_DT relative_JJ intensity_NN of_IN the_DT
          larger_JJR AR_NNP allele_NN (_( higher_JJR molecular_JJ weight_NN ,_, peak_NN 2_LS )_) with_IN
          respect_NN to_TO the_DT smaller_JJR AR_NNP allele_NN (_( low_JJ molecular_JJ weight_NN ,_,
          peak_NN 1_LS )_) was_VBD calculated_VBN and_CC expressed_VBN as_IN the_DT ratio_NN R_NN (_( peak_NN
          2_CD area_NN /_NN peak_NN 1_CD area_NN )_) ._. The_DT ratios_NNS in_IN the_DT mock-digested_JJ (_( R_NNP 
          M_NNP )_) and_CC HpaII-digested_NNP (_( R_NNP 
          H_NNP )_) samples_NNS were_VBD calculated_VBN
          separately_RB ,_, and_CC were_VBD then_RB averaged_VBN for_IN each_DT of_IN the_DT two_CD
          sets_NNS of_IN duplicate_VB samples_NNS ._. For_IN each_DT individual_NN ,_, a_DT
          normalized_JJ ratio_NN (_( R_NNP 
          N_NNP =_SYM R_NNP 
          H_NNP /_NN R_NNP 
          M_NNP )_) was_VBD calculated_VBN to_TO correct_VB for_IN
          occasional_JJ minor_JJ variation_NN in_IN efficiency_NN of_IN amplification_NN
          of_IN the_DT two_CD AR_NNP alleles_NNS ._. This_DT normalized_JJ ratio_NN was_VBD used_VBN to_TO
          determine_VB the_DT percentage_NN of_IN inactivation_NN of_IN the_DT X_NNP
          chromosome_NN bearing_VBG the_DT larger_JJR AR_NNP allele_NN :_: percentage_NN
          inactivation_NN =_SYM [_NN R_NNP 
          N_NNP /_NN (_( R_NNP 
          N_NNP +_NN 1_LS )_) ]_NN ×_NN 100_CD ._. The_DT degree_NN of_IN skewing_VBG
          was_VBD calculated_VBN by_IN subtracting_VBG 50_CD from_IN the_DT observed_VBN degree_NN
          of_IN inactivation_NN ._.
        
      
      
        Results_NNS
        
          Fluorescent_NNP Hpa_NNP II_NNP /_NN polymerase_NN chain_NN reaction_NN assay_NN
          for_IN X-_NNP chromosome_NN inactivation_NN
          Employing_NNP a_DT modification_NN of_IN previously_RB described_VBD
          methods_NNS [_NN 11_CD ]_NN ,_, we_PRP utilized_JJ a_DT fluorescent_NN Hpa_NNP II_NNP /_NN PCR_NNP assay_NN
          of_IN the_DT AR_NNP locus_JJ to_TO assess_VB X-_NNP chromosome_NN inactivation_NN
          patterns_NNS ._. As_IN shown_VBN in_IN Fig_NNP ._. 3_LS ,_, the_DT AR_NNP gene_NN contains_VBZ a_DT
          polymorphic_JJ CAG_NNP repeat_NN that_WDT is_VBZ flanked_JJ by_IN Hpa_NNP II_NNP sites_NNS ._.
          These_DT Hpa_NNP II_NNP sites_NNS are_VBP methylated_JJ on_IN the_DT inactive_JJ X_NNP
          chromosome_NN ,_, and_CC are_VBP unmethylated_JJ on_IN the_DT active_JJ X_NNP
          chromosome_NN ._. By_IN performing_VBG PCR_NNP amplification_NN across_IN this_DT
          region_NN after_IN cutting_VBG with_IN the_DT methylation-sensitive_JJ
          enzyme_NN Hpa_NNP II_NNP ,_, the_DT relative_JJ amounts_NNS of_IN the_DT methylated_JJ AR_NNP
          alleles_NNS can_MD be_VB quantitatively_RB determined_VBN with_IN a_DT high_JJ
          degree_NN of_IN accuracy_NN ;_: variance_NN on_IN repeated_VBN assays_NNS is_VBZ
          approximately_RB 4_CD %_NN [_NN 12_CD ]_NN ._.
          Two_CD examples_NNS of_IN this_DT assay_NN are_VBP shown_VBN in_IN Fig_NNP ._. 4_LS ._. In_IN
          Fig_NNP ._. 4_LS a_DT ,_, an_DT individual_NN with_IN equivalent_NN methylation_NN of_IN
          both_DT AR_NNP alleles_NNS is_VBZ shown_VBN ._. In_IN this_DT case_NN ,_, the_DT relative_JJ peak_NN
          intensity_NN is_VBZ equivalent_NN in_IN the_DT mock-digested_JJ and_CC Hpa_NNP
          II-digested_NNP samples_NNS ._. In_IN Fig_NNP ._. 4_LS b_SYM ,_, an_DT individual_NN with_IN
          extremely_RB skewed_VBN X_NNP inactivation_NN is_VBZ shown_VBN ,_, in_IN whom_WP the_DT
          lower_JJR allele_NN (_( 271_CD bp_NN )_) is_VBZ relatively_RB over-methylated_JJ
          compared_VBN with_IN the_DT upper_JJ (_( 284_CD bp_NN )_) allele_NN ._. Thus_RB ,_, the_DT X_NNP
          chromosome_NN bearing_VBG the_DT lower_JJR allele_NN is_VBZ preferentially_RB
          inactivated_JJ ._. As_IN described_VBD in_IN the_DT Materials_NNPS and_CC method_NN
          section_NN ,_, all_DT assays_NNS were_VBD normalized_JJ to_TO the_DT mock_JJ results_NNS
          and_CC performed_VBN in_IN duplicate_VB ._. Skewing_NNP of_IN X-_NNP chromosome_NN
          inactivation_NN is_VBZ expressed_VBN as_IN a_DT percentage_NN deviation_NN from_IN
          equal_JJ (_( 50_CD :_: 50_CD )_) inactivation_NN of_IN the_DT upper_JJ and_CC lower_JJR AR_NNP
          alleles_NNS ._. Therefore_RB ,_, the_DT maximal_NN possible_JJ deviation_NN is_VBZ
          50_CD %_NN ,_, in_IN which_WDT case_NN all_DT of_IN the_DT X_NNP chromosome_NN bearing_NN one_CD of_IN
          the_DT AR_NNP alleles_NNS are_VBP inactivated_JJ ._.
        
        
          Comparison_NNP of_IN X-_NNP chromosome_NN inactivation_NN patterns_NNS in_IN
          normal_JJ females_NNS and_CC females_NNS with_IN autoimmune_JJ
          diseases_NNS
          We_PRP examined_VBD X-_NNP chromosome_NN inactivation_NN patterns_NNS in_IN
          several_JJ different_JJ populations_NNS ._. The_DT results_NNS are_VBP summarized_VBD
          in_IN Fig_NNP ._. 1_LS ._. A_DT wide_JJ range_NN of_IN X-_NNP inactivation_NN skewing_VBG was_VBD
          observed_VBN in_IN all_DT five_CD groups_NNS ._. Approximately_RB 5_CD %_NN (_( nine_CD out_IN
          of_IN 197_CD )_) of_IN individuals_NNS exhibited_VBN extreme_JJ skewing_VBG (_( greater_JJR
          than_IN 40_CD %_NN deviation_NN from_IN a_DT 50_CD :_: 50_CD distribution_NN )_) ._. However_RB ,_,
          there_EX was_VBD no_DT difference_NN between_IN the_DT groups_NNS ,_, either_CC in_IN the_DT
          overall_JJ mean_NN skewing_VBG ,_, or_CC in_IN the_DT fraction_NN of_IN individuals_NNS
          with_IN extreme_JJ skewing_VBG (_( >_NN 40_CD %_NN )_) ._.
        
        
          Androgen_NNP receptor_NN gene_NN allele_NN size_NN comparisons_NNS
          among_IN patients_NNS and_CC controls_NNS
          Although_IN the_DT present_JJ study_NN was_VBD not_RB initiated_VBN to_TO
          examine_VB allelic_JJ variation_NN in_IN the_DT AR_NNP gene_NN 
          per_IN se_FW ,_, the_DT data_NNS provide_VBP an_DT
          opportunity_NN to_TO address_VB this_DT question_NN ._. Excessively_NNP long_JJ
          CAG_NNP repeats_VBZ in_IN the_DT AR_NNP gene_NN are_VBP a_DT rare_JJ cause_NN of_IN
          spinal-bulbar_JJ muscular_JJ atrophy_NN [_NN 13_CD ]_NN ,_, and_CC AR_NNP repeat_NN
          length_NN appears_VBZ to_TO have_VB an_DT influence_NN on_IN the_DT biology_NN of_IN
          certain_JJ tumors_NNS [_NN 14_CD ,_, 15_CD ]_NN ._. In_IN this_DT context_NN ,_, it_PRP has_VBZ been_VBN
          shown_VBN [_NN 16_CD ]_NN that_DT transcription_NN of_IN the_DT AR_NNP gene_NN correlates_NNS
          inversely_RB with_IN repeat_NN length_NN ._. We_PRP therefore_RB compared_VBD AR_NNP
          repeat_NN length_NN in_IN control_NN individuals_NNS and_CC patients_NNS with_IN
          autoimmunity_NN ._. No_DT differences_NNS were_VBD observed_VBN for_IN mean_NN
          repeat_NN length_NN ,_, or_CC for_IN maximum_NN and_CC minimum_JJ repeat_NN length_NN ,_,
          among_IN the_DT five_CD groups_NNS ._.
        
      
      
        Discussion_NNP
        The_DT reason_NN for_IN the_DT female_JJ predominance_NN in_IN most_JJS
        autoimmune_JJ diseases_NNS remains_VBZ obscure_JJ ._. The_DT present_JJ study_NN was_VBD
        initiated_VBN in_IN order_NN to_TO address_VB the_DT hypothesis_NNS that_IN a_DT
        nonhormonal_NN mechanism_NN related_VBN to_TO X_NNP inactivation_NN might_MD be_VB
        involved_VBN ._. The_DT hypothesis_NNS rests_VBZ on_IN the_DT idea_NN that_IN skewing_VBG of_IN
        X_NNP inactivation_NN might_MD lead_VB to_TO a_DT deficiency_NN of_IN tolerance_NN
        induction_NN in_IN the_DT thymus_JJ ,_, particularly_RB with_IN respect_NN to_TO
        polymorphic_JJ X-_NNP linked_VBD autoantigens_NNS ._. The_DT hypothesis_NNS predicts_VBZ
        that_WDT skewed_VBN X_NNP inactivation_NN would_MD be_VB more_RBR prevalent_JJ in_IN
        females_NNS with_IN autoimmune_JJ diseases_NNS than_IN in_IN female_JJ control_NN
        individuals_NNS ._. This_DT was_VBD not_RB observed_VBN ._.
        Nevertheless_RB ,_, these_DT negative_JJ data_NN do_VBP not_RB rule_VB out_RP a_DT role_NN
        for_IN X_NNP inactivation_NN in_IN female_JJ predisposition_NN to_TO loss_NN of_IN
        tolerance_NN ._. A_DT general_JJ model_NN for_IN how_WRB this_DT mechanism_NN might_MD
        operate_VB is_VBZ shown_VBN in_IN Fig_NNP ._. 1_LS ._. Thymocytes_NNP undergo_VBP selection_NN in_IN
        the_DT thymic_JJ parenchyma_NN ,_, and_CC in_IN the_DT case_NN of_IN negative_JJ
        selection_NN ,_, the_DT selecting_VBG elements_NNS appear_VBP to_TO be_VB derived_VBN from_IN
        the_DT bone_NN marrow_NN and_CC consist_VBP mainly_RB of_IN thymic_JJ dendritic_JJ
        cells_NNS ._. If_IN the_DT thymic_JJ dendritic_JJ cell_NN population_NN exhibits_VBZ
        random_JJ X_NNP inactivation_NN ,_, it_PRP is_VBZ highly_RB likely_JJ that_IN
        differentiating_VBG thymocytes_NNS will_MD contact_VB dendritic_JJ cells_NNS
        that_WDT express_VBP self-antigens_JJ on_IN both_DT X_NNP chromosomes_NNS ._. This_DT
        situation_NN is_VBZ outlined_VBN schematically_RB on_IN the_DT left_NN side_NN of_IN
        Fig_NNP ._. 2_LS ._. However_RB ,_, if_IN there_EX is_VBZ extremely_RB skewed_VBN X_NNP
        inactivation_NN in_IN the_DT thymic_JJ dendritic_JJ cell_NN population_NN ,_, a_DT
        particular_JJ thymocyte_NN may_MD not_RB come_VB into_IN contact_NN with_IN
        dendritic_JJ cells_NNS that_WDT express_VBP one_CD of_IN the_DT two_CD X_NNP chromosomes_NNS ._.
        This_DT would_MD lead_VB to_TO a_DT situation_NN where_WRB T_NN cells_NNS may_MD undergo_VB
        thymic_JJ maturation_NN without_IN having_VBG been_VBN negatively_RB selected_VBN
        for_IN antigens_NNS that_WDT are_VBP expressed_VBN on_IN the_DT predominantly_RB
        inactive_JJ X_NNP chromosome_NN ._. This_DT situation_NN is_VBZ shown_VBN on_IN the_DT right_JJ
        side_NN of_IN Fig_NNP ._. 2_LS ._.
        In_IN order_NN for_IN this_DT mechanism_NN to_TO be_VB physiologically_RB
        relevant_JJ ,_, several_JJ assumptions_NNS must_MD be_VB made_VBN ._. First_LS ,_,
        defective_JJ tolerance_NN from_IN skewed_VBN X_NNP inactivation_NN should_MD only_RB
        be_VB directed_VBN at_IN X-_NNP linked_VBD antigens_NNS that_WDT are_VBP polymorphic_JJ ,_, and_CC
        for_IN which_WDT the_DT individual_NN is_VBZ heterozygous_JJ ._. Thus_RB ,_, this_DT
        mechanism_NN would_MD not_RB be_VB expected_VBN to_TO commonly_RB lead_VB to_TO lack_NN of_IN
        tolerance_NN unless_IN there_RB are_VBP at_IN least_JJS several_JJ highly_RB
        polymorphic_JJ X-_NNP linked_VBD autoantigens_NNS in_IN the_DT population_NN that_WDT
        are_VBP involved_VBN in_IN thymic_JJ deletion_NN events_NNS ._. Second_JJ ,_, if_IN this_DT
        actually_RB leads_VBZ to_TO autoimmunity_NN ,_, it_PRP also_RB predicts_VBZ that_IN the_DT
        initial_JJ break_NN in_IN tolerance_NN that_WDT leads_VBZ to_TO disease_NN should_MD
        involve_VB an_DT X-_NNP linked_VBD autoantigen_NN that_WDT is_VBZ expressed_VBN in_IN a_DT
        peripheral_JJ nontolerizing_VBG site_NN or_CC circumstance_NN ._.
        A_DT recent_JJ report_NN [_NN 7_CD ]_NN elegantly_RB demonstrated_VBD the_DT
        importance_NN of_IN thymic_JJ deletion_NN events_NNS in_IN predisposing_VBG to_TO
        autoimmune_JJ disease_NN ._. The_DT PLP_NNP autoantigen_NN is_VBZ expressed_VBN in_IN
        alternatively_RB spliced_JJ forms_NNS ,_, which_WDT exhibit_NN tissue-specific_JJ
        expression_NN ._. A_DT nonspliced_JJ variant_NN is_VBZ expressed_VBN in_IN periperal_NN
        neural_NN tissue_NN ._. However_RB ,_, in_IN the_DT thymus_JJ a_DT splice_NN variant_NN
        results_NNS in_IN the_DT lack_NN of_IN thymic_JJ expression_NN of_IN an_DT
        immunodominant_NN peptide_NN ._. This_DT results_NNS in_IN loss_NN of_IN tolerace_NN of_IN
        T_NN cells_NNS to_TO this_DT peptide_NN ,_, presumably_RB on_IN the_DT basis_NN of_IN lack_NN of_IN
        thymic_JJ deletion_NN of_IN thymocytes_NNS that_WDT are_VBP reactive_JJ with_IN this_DT
        antigen_NN ._. Interestingly_RB ,_, PLP_NNP is_VBZ encoded_JJ on_IN the_DT X_NNP chromsome_NN ._.
        However_RB ,_, there_EX is_VBZ no_DT evidence_NN that_IN genetic_JJ polymorphisms_NNS
        control_VBP the_DT level_NN splicing_VBG of_IN PLP_NNP within_IN the_DT thymus_JJ ._.
        Nevertheless_RB ,_, these_DT data_NNS illustrate_VBP the_DT potential_JJ
        importance_NN of_IN deficiencies_NNS in_IN thymic_JJ deletion_NN for_IN
        autoimmune_JJ T-_NNP cell_NN reactivity_NN ._.
        The_DT present_JJ results_NNS suggest_VBP that_IN if_IN skewed_VBN X_NNP
        inactivation_NN is_VBZ relevant_JJ to_TO induction_NN of_IN thymic_JJ tolerance_NN ,_,
        then_RB the_DT effect_NN does_VBZ not_RB depend_VB on_IN global_JJ skewing_VBG of_IN
        X-_NNP chromosome_NN inactivation_NN ,_, at_IN least_JJS in_IN the_DT hematopoietic_JJ
        compartment_NN ._. In_IN this_DT study_NN we_PRP examined_VBD X-_NNP inactivation_NN
        patterns_NNS in_IN peripheral_JJ blood_NN mononuclear_NN cells_NNS ,_, and_CC the_DT
        results_NNS should_MD reflect_VB the_DT state_NN of_IN X_NNP inactivation_NN in_IN all_DT
        mesenchymal_NN tissues_NNS ,_, including_VBG dendritic_JJ cells_NNS ._. X_NN
        inactivation_NN occurs_VBZ at_IN a_DT very_RB early_JJ time_NN point_NN in_IN
        development_NN ,_, and_CC thus_RB the_DT results_NNS in_IN one_CD tissue_NN should_MD
        reflect_VB the_DT general_JJ situation_NN in_IN the_DT rest_NN of_IN the_DT body_NN ._.
        However_RB ,_, there_EX may_MD be_VB exceptions_NNS to_TO this_DT ._. We_PRP have_VBP
        occasionally_RB observed_VBN differences_NNS in_IN X_NNP inactivation_NN
        patterns_NNS between_IN buccal_NN mucosa_NN (_( an_DT ectodermally_RB derived_VBN
        tissue_NN )_) and_CC peripheral_JJ blood_NN (_( mesoderm_NN )_) in_IN the_DT same_JJ
        individual_JJ (_( unpublished_JJ observations_NNS )_) ._. This_DT could_MD be_VB a_DT
        chance_NN event_NN ,_, or_CC may_MD result_VB from_IN selection_NN for_IN certain_JJ
        X-_NNP linked_VBD alleles_NNS during_IN embryonic_JJ development_NN ,_, as_IN has_VBZ been_VBN
        described_VBN in_IN carriers_NNS of_IN X-_NNP linked_VBD immunodeficiencies_NNS [_NN 17_CD ]_NN ._.
        However_RB ,_, in_IN general_JJ ,_, subsets_NNS of_IN cells_NNS within_IN the_DT
        hematopoietic_JJ compartment_NN do_VBP not_RB display_VB differences_NNS in_IN
        X-_NNP inactivation_NN patterns_NNS (_( unpublished_JJ observations_NNS )_) ._.
        Another_DT consideration_NN is_VBZ that_IN certain_JJ tissue_NN
        microenvironments_NNS may_MD be_VB derived_VBN from_IN very_RB small_JJ numbers_NNS of_IN
        founder_NN cells_NNS ,_, and_CC thus_RB may_MD exhibit_VB skewed_VBN utilization_NN of_IN
        one_CD or_CC the_DT other_JJ X_NNP chromosome_NN ,_, even_RB if_IN the_DT tissue_NN as_IN a_DT
        whole_NN is_VBZ not_RB skewed_VBN ._. This_DT situation_NN could_MD vary_VB over_IN time_NN ._.
        Thus_RB ,_, there_EX may_MD be_VB time_NN points_NNS at_IN which_WDT certain_JJ thymic_JJ
        microenvironments_NNS are_VBP populated_VBN by_IN dendritic_JJ cells_NNS that_IN ,_,
        for_IN stochastic_JJ reasons_NNS ,_, all_DT utilize_VB the_DT same_JJ X_NNP chromosome_NN ._.
        This_DT would_MD create_VB a_DT `_`` window_NN of_IN opportunity_NN '_'' in_IN which_WDT a_DT
        given_VBN thymocyte_NN ,_, in_IN a_DT given_VBN selecting_VBG location_NN ,_, could_MD
        escape_VB negative_JJ selection_NN by_IN antigens_NNS on_IN the_DT inactive_JJ X_NNP
        chromosome_NN ._. The_DT likelihood_NN of_IN this_DT happening_VBG would_MD
        obviously_RB depend_VB on_IN the_DT number_NN of_IN dendritic_JJ cells_NNS that_WDT are_VBP
        usually_RB contacted_VBN by_IN a_DT thymocyte_NN during_IN thymic_JJ selection_NN ._.
        There_EX is_VBZ limited_VBN information_NN on_IN this_DT point_NN ,_, although_IN
        Stewart_NNP [_NN 10_CD ]_NN has_VBZ theorized_VBD that_IN this_DT number_NN may_MD be_VB as_RB low_JJ
        as_IN 15_CD ._. If_IN this_DT is_VBZ the_DT case_NN ,_, escape_VB from_IN thymic_JJ deletion_NN may_MD
        still_RB occur_VB in_IN females_NNS who_WP are_VBP heterozygous_JJ for_IN a_DT relevant_JJ
        X-_NNP linked_VBD antigen_NN ,_, even_RB if_IN the_DT hematopoietic_JJ cells_NNS in_IN
        general_JJ do_VBP not_RB exhibit_VB extreme_JJ skewing_VBG ._.
        If_IN the_DT latter_JJ scenario_NN is_VBZ operative_JJ ,_, it_PRP will_MD be_VB
        extremely_RB difficult_JJ to_TO document_VB it_PRP by_IN studying_VBG
        X-_NNP inactivation_NN patterns_NNS ._. One_PRP might_MD examine_VB X-_NNP inactivation_NN
        skewing_VBG specifically_RB in_IN thymic_JJ dendritic_JJ populations_NNS ,_, but_CC
        if_IN the_DT effect_NN is_VBZ at_IN the_DT level_NN of_IN microenvironment_NN and_CC
        varies_VBZ over_IN time_NN ,_, then_RB it_PRP will_MD not_RB be_VB possible_JJ to_TO detect_VB
        this_DT using_VBG methods_NNS directed_VBN at_IN large_JJ cell_NN populations_NNS ,_, as_IN
        we_PRP have_VBP done_VBN here_RB ._. Conceivably_RB ,_, examination_NN of_IN thymic_JJ
        tissue_NN sections_NNS could_MD provide_VB support_NN for_IN the_DT hypothesis_NNS ._.
        Another_DT aspect_NN of_IN this_DT is_VBZ that_IN some_DT thymic_JJ deletion_NN events_NNS
        appear_VBP to_TO be_VB mediated_JJ by_IN thymic_JJ epithelial_NN cells_NNS at_IN the_DT
        cortico-medullary_JJ junction_NN ._. Interestingly_RB ,_, thymic_JJ
        epithelial_NN cells_NNS appear_VBP to_TO be_VB derived_VBN from_IN very_RB few_JJ founder_NN
        cells_NNS [_NN 18_CD ]_NN ,_, and_CC thus_RB should_MD exhibit_VB a_DT rather_RB large_JJ degree_NN
        of_IN `_`` patchiness_NNS '_'' with_IN respect_NN to_TO X_NNP inactivation_NN ._. This_DT again_RB
        might_MD lead_VB to_TO local_JJ epithelial_NN cell_NN microenvironments_NNS that_WDT
        fail_VBP to_TO delete_VB for_IN X-_NNP linked_VBD autoantigens_NNS ._.
        It_PRP has_VBZ recently_RB become_VBN apparent_JJ that_IN mechanisms_NNS of_IN
        peripheral_JJ tolerance_NN also_RB exist_VB ,_, and_CC we_PRP have_VBP considered_VBN the_DT
        possibility_NN that_WDT skewed_VBN X_NNP inactivation_NN in_IN a_DT peripheral_JJ
        tolerizing_VBG compartment_NN might_MD also_RB lead_VB to_TO inefficient_JJ
        tolerance_NN ._. A_DT major_JJ mechanism_NN of_IN peripheral_JJ tolerance_NN
        induction_NN appears_VBZ to_TO involve_VB the_DT recognition_NN of_IN tolerizing_VBG
        antigens_NNS by_IN T_NN cells_NNS in_IN the_DT absence_NN of_IN costimulation_NN [_NN 19_CD ]_NN ._.
        This_DT may_MD specifically_RB occur_VB in_IN the_DT paracortical_JJ regions_NNS of_IN
        lymph_NN nodes_NNS ,_, without_IN further_JJ progression_NN of_IN the_DT tolerized_JJ T_NN
        cells_NNS into_IN lymph_NN node_NN follicles_NNS ._. Because_IN this_DT mechanism_NN
        presumably_RB involves_VBZ circulating_VBG antigen_NN ,_, it_PRP is_VBZ difficult_JJ to_TO
        invoke_VB a_DT role_NN for_IN X-_NNP inactivation_NN skewing_VBG in_IN altering_VBG this_DT
        process_NN ,_, unless_IN the_DT skewing_VBG were_VBD virtually_RB complete_JJ ._.
        Tolerance_NNP induction_NN by_IN parenchymal_NN tissue_NN has_VBZ also_RB been_VBN
        described_VBN [_NN 20_CD ]_NN ,_, and_CC may_MD be_VB a_DT multistage_NN process_NN that_WDT is_VBZ
        still_RB not_RB entirely_RB understood_VBN ._. Conceivably_RB ,_, skewed_VBN
        expression_NN of_IN X-_NNP linked_VBD autoantigens_NNS could_MD play_VB a_DT role_NN here_RB ,_,
        but_CC this_DT would_MD require_VB invoking_VBG a_DT peripheral_JJ tolerizing_VBG
        compartment_NN that_WDT is_VBZ limiting_VBG with_IN respect_NN to_TO the_DT dosage_NN of_IN
        tolerizing_VBG cells_NNS to_TO which_WDT peripheral_JJ T_NN cells_NNS can_MD be_VB
        exposed_VBN ._. No_DT such_JJ compartment_NN has_VBZ yet_RB been_VBN defined_VBN ._.
        In_IN conclusion_NN ,_, we_PRP suggest_VBP that_IN X-_NNP chromosome_NN inactivation_NN
        needs_VBZ to_TO be_VB considered_VBN as_IN a_DT potential_JJ factor_NN in_IN the_DT
        predominance_NN of_IN females_NNS in_IN most_JJS autoimmune_JJ diseases_NNS ._. Our_PRP$
        inability_NN to_TO show_VB an_DT increase_NN in_IN X-_NNP chromosome_NN skewing_VBG in_IN
        females_NNS with_IN autoimmunity_NN does_VBZ not_RB eliminate_VB this_DT as_IN an_DT
        etiologic_JJ contributor_NN to_TO loss_NN of_IN immunologic_JJ tolerance_NN ._.
        Future_JJ experiments_NNS must_MD be_VB directed_VBN at_IN detailed_JJ analysis_NN of_IN
        tissue_NN patterns_NNS of_IN X_NNP inactivation_NN ,_, as_RB well_RB as_IN at_IN a_DT search_NN
        for_IN potential_JJ X-_NNP linked_VBD autoantigens_NNS ._.
      
    
  
